Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TARSARC study
2018-003835-31Phase 2Active
- Sponsor
- Institut Bergonié
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in leiomyosarcoma (LMS) comparing Berzosertib + gemcitabine with Gemcitabine alone (2 arms). Primary endpoint: 6-month progression-free rate. Started Jun 2021; status: active.
02
Drugs
berzosertibgemcitabine
03
Conditions
leiomyosarcoma (LMS)
Beyond the preview
Go deeper on 2018-003835-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003835-31.